Acetazolamide: Clinical Overview
Primary Indications
Acetazolamide is indicated for central sleep apnea (multiple etiologies), idiopathic intracranial hypertension, acute decompensated heart failure with volume overload, and acute mountain sickness, with dosing and efficacy varying significantly by condition.
Central Sleep Apnea
- Recommended for: Primary CSA, CSA due to heart failure, medication/substance-induced CSA, treatment-emergent CSA, CSA due to medical conditions, and high-altitude CSA 1
- Efficacy: Clinically meaningful improvements in AHI (apnea-hypopnea index) and excessive sleepiness, though cardiovascular parameters show limited improvement 1
- Evidence quality: Low to very low certainty, based on short-duration studies (3-6 nights for most conditions, 1-2 nights for altitude) 1
Idiopathic Intracranial Hypertension (IIH)
- Dosing approach: Start 250-500 mg twice daily, titrate upward as tolerated 2
- Maximum dose: 4 g daily (though only 44% of patients in trials achieved this; majority tolerated 1 g/day) 2
- Important caveat: Acetazolamide has NOT been shown effective for headache treatment alone in IIH 2
- Uncertainty: Not all UK clinicians prescribe acetazolamide for IIH due to limited evidence and side effect profile 2
Acute Decompensated Heart Failure
- Dosing: 500 mg IV once daily added to loop diuretics 3
- Efficacy: 42.2% successful decongestion vs 30.5% with placebo (risk ratio 1.46,95% CI 1.17-1.82, P<0.001) 3
- Mechanism: Improves diuretic efficiency by blocking proximal tubular sodium reabsorption, resulting in higher cumulative urine output and natriuresis 3, 4
- Critical monitoring: Follow-up electrolytes essential, as acetazolamide may disturb acid-base balance and cause arrhythmias in hyperventilating HF patients 1
Acute Mountain Sickness Prevention
- Dosing: 250 mg/day effective, though dose-response exists (250,500,750 mg/day studied) 5
- Efficacy varies by ascent speed:
- Climbing (14 m/h): NNT 6.5 with 250 mg/day
- Transport then climbing (133 m/h): NNT 3.7 with 250 mg/day
- Transport alone (491 m/h): NNT 2.6 with 250 mg/day 5
Dosing Regimens by Indication
| Indication | Starting Dose | Maximum Dose | Duration |
|---|---|---|---|
| IIH | 250-500 mg BID | 4 g/day | Long-term |
| CSA (general) | 250-1000 mg/day | 1000 mg/day | Ongoing |
| CSA (altitude) | 250 mg/day | 250 mg/day | 1-2 nights |
| ADHF | 500 mg IV daily | 500 mg/day | 3 days |
| AMS prevention | 250 mg/day | 750 mg/day | Duration at altitude |
Renal dosing: Do not administer more frequently than every 12 hours if CrCl <50 mL/min 6
Contraindications (FDA Label)
Absolute contraindications 7:
- Hypersensitivity to acetazolamide or sulfonamides (cross-sensitivity possible)
- Depressed sodium and/or potassium serum levels
- Marked kidney or liver disease/dysfunction
- Suprarenal gland failure
- Hyperchloremic acidosis
- Cirrhosis (risk of hepatic encephalopathy)
- Chronic non-congestive angle-closure glaucoma (long-term use)
Adverse Effects
Common Side Effects (Dose-Dependent)
Most frequent adverse effects are paraesthesias, dysgeusia, and polyuria, with clear dose-response relationships 8:
- Paraesthesias: NNH 2.3 (95% CI 2-2.7) - increases with higher doses (beta=1.8, P=0.01) 8
- Dysgeusia (taste disturbance): NNH 18 (95% CI 10-38) - increases with higher doses (beta=3.1, P=0.02) 8
- Polyuria: NNH 17 (95% CI 9-49) - risk increases with 500-750 mg/day 8, 5
- Fatigue: NNH 11 (95% CI 6-24) - trend toward dose-dependence (beta=2.6, P=0.14) 8
Additional Recognized Side Effects
Serious but Rare
- Renal stones 2, 1
- Hypokalemia 1
- Arrhythmias (theoretical risk in HF patients due to electrolyte disturbances) 1
Safety Profile
Acetazolamide is generally well-tolerated; serious side effects are rare when patients are correctly selected 9. The ADVOR trial found similar incidence of worsening kidney function, hypokalemia, hypotension, and adverse events between acetazolamide and placebo groups 3.
Critical Clinical Pearls
Monitoring Requirements
- For HF patients: Reassess electrolytes, AHI, sleep quality, cardiac function, and side effects after 2-4 weeks 1
- Avoid in cirrhosis: High risk of hepatic encephalopathy 7
- Renal adjustment: Highly protein-bound, primarily renally eliminated; adjust frequency for CrCl <50 mL/min 6
Drug Interactions
- Reduces efficacy of oral contraceptives (applies to topiramate, not explicitly stated for acetazolamide in provided evidence, but both are carbonic anhydrase inhibitors)
Formulation
- No consensus on normal vs. modified release formulations 2
- IV formulation: 500 mg vial, reconstituted solution stable 12 hours refrigerated 7